Multiple endogenous receptors and pathways

The term "Multiple endogenous receptors and pathways" is a non-specific, aggregate descriptor used to characterize the broad pharmacological activity of substances that lack a single, primary molecular target. This designation is frequently applied in clinical literature and regulatory filings to complex therapeutic agents, such as intravenous immunoglobulin (IVIG) or polyherbal formulations, which exert their effects through the simultaneous modulation of various signaling cascades, cell surface receptors, and enzymatic processes (NCBI/PubMed). From a drug discovery perspective, this entry is considered "incorrect" or "too broad" because it does not identify a discrete, sequence-validated protein or gene product (UniProt). While agents described this way may have significant therapeutic utility, the lack of a defined target makes traditional pharmacodynamic modeling and precision patient selection exceptionally challenging (Nature Reviews Drug Discovery). Consequently, this term serves as a placeholder for mechanisms that are either multi-faceted or not yet fully elucidated at the molecular level (IUPHAR/BPS Guide to Pharmacology). It represents a systems-level interaction rather than a molecular-level interaction, which complicates the assessment of toxicity and efficacy. As such, it is not a valid entry for structured target-based drug design or precision medicine initiatives.

Other names

Multi-targetPleiotropic pathwaysNon-specific endogenous targetsSystemic endogenous modulation

Not applicable as this is a generic grouping rather than a specific molecular entity.